Veliparib alone or in combination with mitomycin C in patients with solid tumors with functional deficiency in homologous recombination repair

Journal of the National Cancer Institute

Volumn 108, Issue 7, 2016, Pages

  Villalona Calero, Miguel A ^a,b,e   Duan, Wenrui ^a,b   Zhao, Weiqiang ^a   Shilo, Konstantin ^a   Schaaf, Larry J ^b   Thurmond, Jennifer ^b   Westman, Judith A ^a   Marshall, John ^c   Xiaobai, Li ^a   Ji, Jiuping ^d   Rose, Jeffrey ^a   Lustberg, Maryam ^a   Bekaii Saab, Tanios ^a,b   Chen, Alice ^d   Timmers, Cynthia ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e Miami Cancer Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CARBOPLATIN; DOXORUBICIN; FANCONI ANEMIA GROUP C PROTEIN; FANCONI ANEMIA GROUP D2 PROTEIN; HISTONE H2AX; MITOMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; VELIPARIB; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BILE DUCT CARCINOMA; BLADDER CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; DIARRHEA; DYSGEUSIA; ENDOMETRIUM CANCER; FANCONI ANEMIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENE SEQUENCE; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; IMMUNOFLUORESCENCE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MESOTHELIOMA; MISSENSE MUTATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; NONSENSE MUTATION; OVARY CANCER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RECOMBINATION REPAIR; RECOMMENDED DRUG DOSE; SIDE EFFECT; SMALL CELL LUNG CANCER; SMALL INTESTINE CANCER; SOLID TUMOR; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; UTERUS CANCER; VOMITING; CHEMICALLY INDUCED; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG EFFECTS; FEASIBILITY STUDY; GENETICS; GERMLINE MUTATION; MIDDLE AGED; NEOPLASMS; PEDIGREE; TUMOR SUPPRESSOR GENE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZIMIDAZOLES; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; FANCONI ANEMIA; FATIGUE; FEASIBILITY STUDIES; FEMALE; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASMS; PEDIGREE; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; RECOMBINATIONAL DNA REPAIR; THROMBOCYTOPENIA;

EID: 84968720519     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv437     Document Type: Article

References (58)

1. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913-917.
2. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917-921.
3. Tutt A, Robson M, Garber J, et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol. 2009;27(Suppl;Ab str CRA501):18s.
4. Fong P, Boss D, Yap T, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123-134.
5. Audeh W, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376(9737):245-251.
6. Bagby GC Jr. Genetic basis of Fanconi anemia. Curr Opin Hematol. 2003;10(1):68-76.
7. D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer. 2003;3:23-34.
8. Reid S, Schindler D, Hanenberg H, et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet. 2007;39(2):162-164.
9. Xia B, Dorsman JC, Ameziane N, et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet. 2007;39(2):159-161.
10. Smogorzewska A, Matsuoka S, Vinciguerra P, et al. Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell. 2007;129(2):289-301.
11. Kim Y, Lach FP, Desetty R, et al. SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. Nat Genet. 2011;43:138-141.
12. Vaz F, Hanenberg H, Schuster B, et al. Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet. 2010;42:406-409.
13. Machida YJ, Machida Y, Chen Y, et al. UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. Mol Cell. 2006;23(4): 589-596.
14. Meetei AR, Yan Z, Wang W. FANCL replaces BRCA1 as the likely ubiquitin ligase responsible for FANCD2 monoubiquitination. Cell Cycle. 2004;3(2): 179-181.
15. Tischkowitz M, Xia B, Sabbaghian N, et al. Analysis of PALB2/FANCNassociated breast cancer families. Proc Natl Acad Sci U S A. 2007;104(16): 6788-6793.
16. Garcia-Higuera I, Taniguchi T, Ganesan S, et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell. 2000;7(2):249-262.
17. Stoepker C, Hain K, Schuster B, et al. SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. Nat Genet. 2011;43:138-141.
18. Bogliolo M, Schuster B, Stoepker C, et al. Mutations in ERCC4, encoding the DNA-repair endonuclease XPF, cause Fanconi anemia. Am J Hum Genet. 2013;92(5):800-806.
19. Sawyer SL, Tian L, Kken M, et al. Biallelic mutations in BRCA1 cause a new Fanconi Anemia subtype. Cancer Discov. 2015;5(2):135-142.
20. Kwee ML, Poll EH, van de Kamp JJ, de Koning H, Eriksson AW, Joenje H. Unusual response to bifunctional alkylating agents in a case of Fanconi anaemia. Hum Genet. 1983;64(4):384-387.
21. Auerbach AD, Rogatko A, Schroeder-Kurth TM. International Fanconi Anemia Registry: relation of clinical symptoms to diepoxybutane sensitivity. Blood. 1989;73(2):391-396.
22. Alter BP. Cancer in Fanconi anemia, 1927-2001. Blood. 2003;101(5):2072.
23. Thompson LH, Hinz JM. Cellular and molecular consequences of defective fanconi anemia proteins in replication-coupled DNA repair: mechanistic insights. Mutational Res. 2009;668:54-72.
24. Lyakhovich A, Surralles J. Disruption of the Fanconi anemia/BRCA pathway in sporadic cancer. Cancer Lett. 2006;232(1):99-106.
25. Neveling K, Kalb R, Florl AR, et al. Disruption of the FA/BRCA pathway in bladder cancer. Cytogenet Genome Res. 2007;118(2-4):166-176.
26. Taniguchi T, Tischkowitz M, Ameziane N, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med. 2003;9(5):568-574.
27. Zhang J, Wang X, Lin CJ, Couch FJ, Fei P. Altered expression of FANCL confers mitomycin C sensitivity in Calu-6 lung cancer cells. Cancer Biol Ther. 2006;5(12):1632-1636.
28. van der Heijden MS, Brody JR, Dezentje DA, et al. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res. 2005;11(20):7508-7515.
29. Moiseyenko VM, Chubenko VA, Moiseyenko FV, et al. Evidence for clinical efficacy of mitomycin C in heavily pretreated ovarian cancer patients carrying germ-line BRCA1 mutation. Med Oncol. 2014;31(10):199.
30. Sonnenblick A, Kadouri L, Appelbaum L, et al. Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy.Cancer Biol Ther. 2011;12(3):165-168.
31. Tutt A, Ellis P, Kilburn L, et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). San Antonio Breast Cancer Symposium 2014;S3-S01.
32. Duan W, Gao L, Zhao W, et al. Assesment of FANCD2 nuclear foci formation in paraffin embedded tumors: a potential patient enrichment strategy for treatment with DNA interstrand crosslink agents. Transl Res. 2013;161(3): 156-164.
33. Duan W, Gao L, Aguila B, Kalvala A, Otterson GA, Villalona-Calero MA. Fanconi anemia repair pathway dysfunction, a potential therapeutic target in lung cancer. Front Oncol. 2014;19;4:368.
34. Kummar S, Kinders R, Gutierrez ME, et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol. 2009;27(16):2705-2711.
35. Redon C, Nakamura A, Zhang Y, et al. Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers. Clin Cancer Res. 2010;16:4532.
36. Araujo L, Timmers CD, Hlavin-Bell E, et al. Genomic characterization of nonsmall cell lung cancer in African Americans by targeted massively parallel sequencing. J Clin Oncol. 2015;33(17):1966-1973.
37. Eisenhauer E, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
38. Shankar LK, Hoffman JM, Bacharach S, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med. 2006;47:1059-1066.
39. Meindl A, Hellebrand H, Wiek C, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet. 2010;42(5):410-414.
40. Gonzez-Pez A, Lez-Bigas N. Improving the Assessment of the Outcome of Nonsynonymous SNVs with a Consensus Deleteriousness Score, Condel. Am J Hum Genet. 2011;88:440-449.
41. Murai J, Huang SY, Das BB, et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 2012;72(21):5588-5599.
42. Murai J, Huang SY, Renaud A, et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther. 2014;13(2):433-443.
43. Lord CJ, Ashworth A. Mechanisms of resistance to therapies targeting BRCAmutant cancers. Nat Med. 2013;19(11):1381-1388.
44. Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 2008;68(8):2581-2586.
45. Norquist B, Wurz KA, Pennil CC, et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol. 2011;29(22):3008-3015.
46. Barber LJ, Sandhu S, Chen L, et al. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J Pathol. 2013;229(3):422-429.
47. Cao L, Xu X, Bunting SF, et al. A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency. Mol Cell. 2009;35(4):534-541.
48. Bouwman P, Aly A, Escandell JM, et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol. 2010;17(6):688-695.
49. Luo J, Somilini NL, Elledge SJ. Principles of cancer therapy: Oncogene and non-oncogene addiction. Cell. 2009;136:823-837.
50. Tischler J, Lehner B, Frazer AG. Evolutionary plasticity of genetic interaction networks. Nat Gen. 2008;40:390-391.
51. Daemen A, Wolf DM, Korkola JE, et al. Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib. Breast Cancer Res Treat. 2012;135(2):505-517.
52. Ihnen M, zu Eulenburg C, Kolarova T, et al. Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer. Mol Cancer Ther. 2013;12(6):1002-1015.
53. Watkins JA, Irshad S, Grigoriadis A, Tutt AN. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res. 2014;3;16(3):211.
54. Wolf DM, Yau C, Sanil A, et al. Evaluation of an in vitro derived signature of olaparib response (PARPi-7) as a predictive biomarker of response to veliparib/ carboplatin plus standard neoadjuvant therapy in high risk breast ccer: Results from the I-SPY 2 Trial. San Antonio Breast Cancer Symposium. 2014;P3-06-05.
55. Shen Y, Rehman FL, Feng Y, et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res. 2013;19(18):5003-5015.
56. First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors. J Clin Oncol Suppl. 2013;31:Abstr 2580.
57. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006;66(16):8109-8115.
58. Pennington KP, Walsh T, Harell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-775.